Skip to main content
. 2014 Apr 11;9(4):e94551. doi: 10.1371/journal.pone.0094551

Figure 5. Effect of anti-NPG-12 antibodies on the PT and APTT of human platelet-poor plasma and binding between anti-NPG-12 antibodies and VKD coagulation factors.

Figure 5

(A) In APTT test, normal platelet-poor plasma was used as a negative control and platelet-poor plasma with 0.1 U/ml heparin as a positive control. No significant difference was observed among the antibody treated groups vs negative control group (n = 3, P>0.05). (B) In PT test, normal platelet-poor plasma was used as a negative control and platelet-poor plasma with 1 U/ml heparin as a positive control. No significant difference was observed among the antibody treated groups vs negative control group (n = 3, P>0.05). (C) In WB test, anti-NPG-12 antibodies combination with hfgl2 expressed by HUVECs at a location of 65 kD was used as a positive control. No detection was observed in the VKD coagulation factor groups. anti-NPG-12: anti-NPG-12 antibodies.